Trends and Drivers of Declining Stroke Mortality in British Columbia: A Population-Based Study (2002-2022).

In Switzerland there is a shortage of population-based information on stroke incidence and case fatalities (CF). The aim of this study was to estimate stroke event rates and both in- and out-of-hospital CF rates. Data on stroke diagnoses, coded according to I60-I64 (ICD 10), were taken from the Federal Hospital Discharge Statistics database (HOST) and the Cause of Death database (CoD) for the year 2004. The number of total stroke events and of age- and gender-specific and agestandardised event rates were estimated; overall CF, in-hospital and out-of-hospital, were determined. Among the overall number of 13 996 hospital discharges from stroke (HOST) the number was lower in women (n = 6736) than in men (n = 7260). A total of 3568 deaths (2137 women and 1431 men) due to stroke were recorded in the CoD database. The number of estimated stroke events was 15 733, and higher in women (n = 7933) than in men (n = 7800). Men presented significantly higher age-specific stroke event rates and a higher age-standardised event rate (178.7/100 000 versus 119.7/100 000). Overall CF rates were significantly higher for women (26.9%) than for men (18.4%). The same was true of out-of-hospital CF but not of in-hospital CF rates. The data on estimated stroke events obtained indicate that stroke discharge rate underestimates the stroke event rate. Out-of-hospital deaths from stroke accounted for the largest proportion of total stroke deaths. Sex differences in both number of total stroke events and deaths could be explained by the higher proportion of women than men aged 55+ in the Swiss population.

Myocardial infarction mortality varies substantially within high-income countries. There is limited guidance on what interventions-including primary and secondary prevention, or improvement of care pathways and quality-can reduce myocardial infarction mortality. Our aim was to understand the contributions of incidence (event rate), pre-hospital deaths, and hospital case fatality to the variations in myocardial infarction mortality within England. We used linked data from national databases on hospitalisations and deaths with acute myocardial infarction (ICD-10 codes I21 and I22) as a primary hospital diagnosis or underlying cause of death, from Jan 1, 2015, to Dec 31, 2018. We used geographical identifiers to estimate myocardial infarction event rate (number of events per 100 000 population), death rate (number of deaths per 100 000 population), total case fatality (proportion of events that resulted in death), pre-hospital fatality (proportion of events that resulted in pre-hospital death), and hospital case fatality (proportion of admissions due to myocardial infarction that resulted in death within 28 days of admission) for men and women aged 45 years and older across 326 districts in England. Data were analysed in a Bayesian spatial model that accounted for similarities and differences in spatial patterns of fatal and non-fatal myocardial infarction. Age-standardised rates were calculated by weighting age-specific rates by the corresponding national share of the appropriate denominator for each measure. From 2015 to 2018, national age-standardised death rates were 63 per 100 000 population in women and 126 per 100 000 in men, and event rates were 233 per 100 000 in women and 512 per 100 000 in men. After age-standardisation, 15·0% of events in women and 16·9% in men resulted in death before hospitalisation, and hospital case fatality was 10·8% in women and 10·6% in men. Across districts, the 99th-to-1st percentile ratio of age-standardised myocardial infarction death rates was 2·63 (95% credible interval 2·45-2·83) in women and 2·56 (2·37-2·76) in men, with death rates highest in parts of northern England. The main contributor to this variation was myocardial infarction event rate, with a 99th-to-1st percentile ratio of 2·55 (2·39-2·72) in women and 2·17 (2·08-2·27) in men across districts. Pre-hospital fatality was greater than hospital case fatality in every district. Pre-hospital fatality had a 99th-to-1st percentile ratio of 1·60 (1·50-1·70) in women and 1·75 (1·66-1·86) in men across districts, and made a greater contribution to variation in total case fatality than did hospital case fatality (99th-to-1st percentile ratio 1·39 [1·29-1·49] and 1·49 [1·39-1·60]). The contribution of case fatality to variation in deaths across districts was largest in women aged 55-64 and 65-74 years and in men aged 55-64, 65-74, and 75-84 years. Pre-hospital fatality was slightly higher in men than in women in most districts and age groups, whereas hospital case fatality was higher in women in virtually all districts at ages up to and including 65-74 years. Most of the variation in myocardial infarction mortality in England is due to variation in myocardial infarction event rate, with a smaller role for case fatality. Most variation in case fatality occurs before rather than after hospital admission. Reducing subnational variations in myocardial infarction mortality requires interventions that reduce event rate and pre-hospital deaths. Wellcome Trust, British Heart Foundation, Medical Research Council (UK Research and Innovation), and National Institute for Health Research (UK).

Quantifying stroke incidence and mortality is crucial for disease surveillance and health system planning. Administrative data offer a cost-effective alternative to "gold standard" population-based studies. However, the optimal methodology for establishing stroke deaths from administrative data remains unclear. We aimed to determine the optimal method for identifying stroke-related deaths in administrative datasets as the fatal component of stroke incidence, comparing counts derived using underlying and all causes of death (CoD). Using whole-population multijurisdictional person-level linked data from hospital and death datasets from South Australia, the Northern Territory, and Western Australia, we identified first-ever stroke events between 2012 and 2015, using underlying CoD and all CoD to identify fatal stroke counts. We determined the 28-day case fatality for both counts and compared results with gold standard Australian population-based stroke incidence studies. The total number of incident stroke events was 16,150 using underlying CoD and 18,074 using all CoD. Case fatality was 24.7% and 32.7% using underlying and all CoD, respectively. Case fatality using underlying CoD was similar to that observed in four Australian "gold standard" population-based studies (20%-24%). Underlying CoD generates fatal incident stroke estimates more consistent with population-based studies than estimates based on stroke deaths identified from all-cause fields in death registers.

The clinical view of case fatality (CF) from acute myocardial infarction (AMI) in those reaching the hospital alive is different from the population view. Registration of both hospitalized AMI cases and out-of-hospital coronary heart disease (CHD) deaths in the WHO MONICA Project allows both views to be reconciled. The WHO MONICA Project provides the largest data set worldwide to explore the relationship between CHD CF and age, sex, coronary event rate, and first versus recurrent event. All 79,669 events of definite AMI or possible coronary death, occurring from 1985 to 90 among 5,725,762 people, 35 to 64 years of age, in 29 MONICA populations are the basis for CF calculations. Age-adjusted CF (percentage of CHD events that were fatal) was calculated across populations, stratified for different time periods, and related to age, sex, and CHD event rate. Median 28-day population CF was 49% (range, 35% to 60%) in men and 51% (range, 34% to 70%) in women and was particularly higher in women than men in populations in which CHD event rates were low. Median 28-day CF for hospitalized events was much lower: in men 22% (range, 15% to 36%) and in women 27% (range, 19% to 46%). Among hospitalized events CF was twice as high for recurrent as for first events. Overall 28-day CF is halved for hospitalized events compared with all events and again nearly halved for hospitalized 24-hour survivors. Because approximately two thirds of 28-day CHD deaths in men and women occurred before reaching the hospital, opportunities for reducing CF through improved care in the acute event are limited. Major emphasis should be on primary and secondary prevention.

ObjectivesTo study trends in stroke mortality rates, event rates, and case fatality, and to explain the extent to which the reduction in stroke mortality rates was influenced by changes in...

In Switzerland there is a shortage of population-based information on stroke incidence and case fatalities (CF). The aim of this study was to estimate stroke event rates and both in- and out-of-hospital CF rates. Data on stroke diagnoses, coded according to I60-I64 (ICD 10), were taken from the Federal Hospital Discharge Statistics database (HOST) and the Cause of Death database (CoD) for the year 2004. The number of total stroke events and of age- and gender-specific and agestandardised event rates were estimated; overall CF, in-hospital and out-of-hospital, were determined. Among the overall number of 13 996 hospital discharges from stroke (HOST) the number was lower in women (n = 6736) than in men (n = 7260). A total of 3568 deaths (2137 women and 1431 men) due to stroke were recorded in the CoD database. The number of estimated stroke events was 15 733, and higher in women (n = 7933) than in men (n = 7800). Men presented significantly higher age-specific stroke event rates and a higher age-standardised event rate (178.7/100 000 versus 119.7/100 000). Overall CF rates were significantly higher for women (26.9%) than for men (18.4%). The same was true of out-of-hospital CF but not of in-hospital CF rates. The data on estimated stroke events obtained indicate that stroke discharge rate underestimates the stroke event rate. Out-of-hospital deaths from stroke accounted for the largest proportion of total stroke deaths. Sex differences in both number of total stroke events and deaths could be explained by the higher proportion of women than men aged 55+ in the Swiss population.

Aim This study examines epidemiological trends of acute myocardial infarction (AMI) in Germany from 2004–2015 across different age groups, using data of the population-based KORA myocardial infarction registry. Methods Annual age-standardised, age-group- and sex-specific mortality and event rates (incident and recurrent) per 100,000 population as well as 28-day case fatality were calculated from all registered cases of AMI and coronary heart disease deaths in 25–74-year-olds from 2004–2015 and 75–84-year-olds from 2009–2015. Average annual percentage changes (AAPC) were calculated by joinpoint regression. Results Mortality rates declined considerably among the elderly (75–84 years), in men by –6.0% annually, due to declines of case fatality by –3.0% and incidence rate by 3.4% and in women by –10.0%, driven by declines in incidence (–9.1%) and recurrence rate (–4.9%). Significant mortality declines also occurred in males, 65–74 years of age (AAPC –3.8%). Among the age groups 25–54 years and 55–64 years, there was no substantial decline in mortality, event rates or case fatality except for a decline of incidence rate in 55–64-year-old men (AAPC –1.8%). Conclusion Inhomogeneous AMI trends across age-groups indicate progress in prevention and treatment for the population >64 years, while among <55-year-olds, we found no significant trend in AMI morbidity and mortality. KEY MESSAGES Age standardised AMI mortality continued to decline from 2009 to 2015 in the study region. Declines in AMI mortality were driven by declines in event rates (both incidence and recurrence rates) and case fatality. AMI trends were inconsistent across different age groups with the strongest declines in mortality and event rates among the elderly population (75–84 years of age).

Drug utilization and outcomes research in multi-ethnic Asian stroke populations is lacking. Our objective was to examine temporal trends and predictors of drug utilization and outcomes in a multi-ethnic Asian stroke population. This registry-based study included ischemic and hemorrhagic first-ever stroke patients hospitalized between 2009 and 2016. Utilization of medications included in-hospital thrombolytic agents, early antithrombotics (antiplatelets, anticoagulants) within 48h of admission, and antithrombotics and statins at discharge. Outcomes analyzed were in-hospital all-cause mortality; 28-day, 90-day, and 1-year case fatality (CF); and discharge destination. Of the 36,615 included patients, 81.6% had ischemic stroke and 18.4% had hemorrhagic stroke (15.5% intracerebral hemorrhage [ICH] and 2.8% subarachnoid hemorrhage [SAH]). For ischemic stroke, the combined use of all three guideline medications (in-hospital thrombolytic therapy, as well as antithrombotics and statins at discharge) increased (P = 0.006). Being on the stroke pathway was associated with prescription of all three guideline medications in ischemic stroke. Decreasing trends for in-hospital mortality, 28-day, 90-day, and 1-year CF and proportion of patients discharged home without rehabilitation appointment were observed in ischemic stroke (P < 0.05) but not in ICH or SAH (apart from 28-day CF). Ischemic stroke patients who received guideline medications were less likely to die or be discharged to nursing homes and chronic sick hospitals. Hemorrhagic stroke patients prescribed statins at discharge were less likely to have 28-day and 1-year CF. Prescription of secondary stroke preventive medications (particularly in ischemic stroke) was associated with more favorable outcomes, highlighting the importance of physician adherence to evidence-based pharmacotherapy.

PurposeInhospital death is commonly used as an outcome measure. However, it may be a biased measure of overall fatal outcome. The objective of this study was to evaluate inhospital death as a measure of all-cause 30-day case fatality in patients with bloodstream infection (BSI).Patients and methodsA population-based surveillance cohort study was conducted, and patients who died in hospital within 30 days (30-day inhospital death) were compared with those who died in any location by day 30 post BSI diagnosis (30-day all-cause case fatality).ResultsA total of 1,773 residents had first incident episodes of BSI. Overall, 299 patients died for a 30-day all-cause case fatality rate of 16.9%. Most (1,587; 89.5%) of the patients were admitted to hospital, and ten (5.4%) of the 186 patients not admitted to hospital died. Of the 1,587 admitted patients, 242 died for a 30-day inhospital death rate of 15.2%. A further 47 patients admitted to hospital died after discharge but within 30 days of BSI diagnosis for a 30-day case fatality rate among admitted patients of 18.2%. Patients who died following discharge within 30 days were older and more likely to have dementia.ConclusionThe use of inhospital death is a biased measure of true case fatality.

&lt;p&gt;Supplementary Table S1. Leading causes of death among females worldwide, 2012 Number of deaths for top ten causes of death among females worldwide Supplementary Table S2. Leading causes of death among females by world region, 2012 Number of deaths for top ten causes of death among females by world region Supplementary Table S3. Estimated number of new cancer cases and deaths among females by world area, 2012 Number of cancer cases and deaths for all cancer sites combined among females by world region Supplementary Figure S1. Female breast cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized breast cancer incidence rates among females and age-standardized breast cancer mortality rates among females Supplementary Figure S2. Female breast cancer incidence trends, age-standardized rate (world), select countries, 1973-2012 Observed age-standardized female breast cancer incidence rates, select countries, all ages, 1973-2012 Supplementary Figure S3. Female breast cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of breast cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S4. Cervical cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized cervical cancer incidence rates and age-standardized cervical cancer mortality rates Supplementary Figure S5. Prevalence (%) of cervical HPV infection among women by region, all types combined, 1995-2009 World map of HPV prevalence (%) among women by world region Supplementary Table S6. Cervical cancer incidence trends, age-standardized rate (world), select countries, 1975-2007 Observed age-standardized cervical cancer incidence rates with a five-year moving average, select countries, all ages, 1975-2007 Supplementary Figure S7. Cervical cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of cervical cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S8. Uterine corpus cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized uterine corpus cancer incidence rates and age-standardized uterine corpus cancer mortality rates Supplementary Figure S9. Uterine corpus cancer mortality trends, age-standardized rate (world), select countries, 1990-2014 Observed age-standardized uterine corpus cancer mortality rates with a five-year moving average, select countries, all ages, 1990-2014 Supplementary Figure S10. Ovarian cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized ovarian cancer incidence rates and age-standardized ovarian cancer mortality rates Supplementary Figure S11. Ovarian cancer mortality trends, age-standardized rate (world), select countries, 1980-2014 Observed age-standardized ovarian cancer mortality rates with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S12. Colorectal cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S13. Colorectal cancer incidence trends, females, select countries, 1980-2014 Observed age-standardized colorectal cancer incidence rates among females with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S14. Colorectal cancer mortality trends, females, age-standardized rate (world), select countries, 1975-2014 Observed age-standardized colorectal cancer mortality rates among females with a five-year moving average, select countries, all ages, 1975-2014 Supplementary Figure S15. Lung cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized lung cancer incidence rates among females and age-standardized lung cancer mortality rates among females Supplementary Figure S16. Population using solid fuels for heating and/or cooking, 2013 World map: percent of the population using solid fuels by country Supplementary Figure S17. Adult female smoking prevalence, age 15+ years, 2013 World map: percent of adult females (age 15+ years) who smoke by country, 2013 Supplementary Figure S18. Female youth smoking prevalence, age 13-15 years, 2011 or latest available data World map: percent of female youth (age 13-15 years) who smoke by country, 2011 or latest available data Supplementary Figure S19. Liver cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S20. Hepatitis B virus prevalence, both sexes, from systematic review of studies 1957-2013 World map of HBV prevalence (%) among both sexes combined by country Supplementary Figure S21. Estimated hepatitis C virus prevalence, both sexes, 2005 World map of HCV prevalence (%) among both sexes combined by country Supplementary Figure S22. Liver cancer mortality trends, females, age-standardized rate (world), select countries, 1995-2014 Observed age-standardized liver cancer mortality rates among females with a five-year moving average, select countries, all ages, 1995-2014&lt;/p&gt;

&lt;p&gt;Supplementary Table S1. Leading causes of death among females worldwide, 2012 Number of deaths for top ten causes of death among females worldwide Supplementary Table S2. Leading causes of death among females by world region, 2012 Number of deaths for top ten causes of death among females by world region Supplementary Table S3. Estimated number of new cancer cases and deaths among females by world area, 2012 Number of cancer cases and deaths for all cancer sites combined among females by world region Supplementary Figure S1. Female breast cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized breast cancer incidence rates among females and age-standardized breast cancer mortality rates among females Supplementary Figure S2. Female breast cancer incidence trends, age-standardized rate (world), select countries, 1973-2012 Observed age-standardized female breast cancer incidence rates, select countries, all ages, 1973-2012 Supplementary Figure S3. Female breast cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of breast cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S4. Cervical cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized cervical cancer incidence rates and age-standardized cervical cancer mortality rates Supplementary Figure S5. Prevalence (%) of cervical HPV infection among women by region, all types combined, 1995-2009 World map of HPV prevalence (%) among women by world region Supplementary Table S6. Cervical cancer incidence trends, age-standardized rate (world), select countries, 1975-2007 Observed age-standardized cervical cancer incidence rates with a five-year moving average, select countries, all ages, 1975-2007 Supplementary Figure S7. Cervical cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of cervical cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S8. Uterine corpus cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized uterine corpus cancer incidence rates and age-standardized uterine corpus cancer mortality rates Supplementary Figure S9. Uterine corpus cancer mortality trends, age-standardized rate (world), select countries, 1990-2014 Observed age-standardized uterine corpus cancer mortality rates with a five-year moving average, select countries, all ages, 1990-2014 Supplementary Figure S10. Ovarian cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized ovarian cancer incidence rates and age-standardized ovarian cancer mortality rates Supplementary Figure S11. Ovarian cancer mortality trends, age-standardized rate (world), select countries, 1980-2014 Observed age-standardized ovarian cancer mortality rates with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S12. Colorectal cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S13. Colorectal cancer incidence trends, females, select countries, 1980-2014 Observed age-standardized colorectal cancer incidence rates among females with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S14. Colorectal cancer mortality trends, females, age-standardized rate (world), select countries, 1975-2014 Observed age-standardized colorectal cancer mortality rates among females with a five-year moving average, select countries, all ages, 1975-2014 Supplementary Figure S15. Lung cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized lung cancer incidence rates among females and age-standardized lung cancer mortality rates among females Supplementary Figure S16. Population using solid fuels for heating and/or cooking, 2013 World map: percent of the population using solid fuels by country Supplementary Figure S17. Adult female smoking prevalence, age 15+ years, 2013 World map: percent of adult females (age 15+ years) who smoke by country, 2013 Supplementary Figure S18. Female youth smoking prevalence, age 13-15 years, 2011 or latest available data World map: percent of female youth (age 13-15 years) who smoke by country, 2011 or latest available data Supplementary Figure S19. Liver cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S20. Hepatitis B virus prevalence, both sexes, from systematic review of studies 1957-2013 World map of HBV prevalence (%) among both sexes combined by country Supplementary Figure S21. Estimated hepatitis C virus prevalence, both sexes, 2005 World map of HCV prevalence (%) among both sexes combined by country Supplementary Figure S22. Liver cancer mortality trends, females, age-standardized rate (world), select countries, 1995-2014 Observed age-standardized liver cancer mortality rates among females with a five-year moving average, select countries, all ages, 1995-2014&lt;/p&gt;

&lt;p&gt;Supplementary Table S1. Leading causes of death among females worldwide, 2012 Number of deaths for top ten causes of death among females worldwide Supplementary Table S2. Leading causes of death among females by world region, 2012 Number of deaths for top ten causes of death among females by world region Supplementary Table S3. Estimated number of new cancer cases and deaths among females by world area, 2012 Number of cancer cases and deaths for all cancer sites combined among females by world region Supplementary Figure S1. Female breast cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized breast cancer incidence rates among females and age-standardized breast cancer mortality rates among females Supplementary Figure S2. Female breast cancer incidence trends, age-standardized rate (world), select countries, 1973-2012 Observed age-standardized female breast cancer incidence rates, select countries, all ages, 1973-2012 Supplementary Figure S3. Female breast cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of breast cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S4. Cervical cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized cervical cancer incidence rates and age-standardized cervical cancer mortality rates Supplementary Figure S5. Prevalence (%) of cervical HPV infection among women by region, all types combined, 1995-2009 World map of HPV prevalence (%) among women by world region Supplementary Table S6. Cervical cancer incidence trends, age-standardized rate (world), select countries, 1975-2007 Observed age-standardized cervical cancer incidence rates with a five-year moving average, select countries, all ages, 1975-2007 Supplementary Figure S7. Cervical cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of cervical cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S8. Uterine corpus cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized uterine corpus cancer incidence rates and age-standardized uterine corpus cancer mortality rates Supplementary Figure S9. Uterine corpus cancer mortality trends, age-standardized rate (world), select countries, 1990-2014 Observed age-standardized uterine corpus cancer mortality rates with a five-year moving average, select countries, all ages, 1990-2014 Supplementary Figure S10. Ovarian cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized ovarian cancer incidence rates and age-standardized ovarian cancer mortality rates Supplementary Figure S11. Ovarian cancer mortality trends, age-standardized rate (world), select countries, 1980-2014 Observed age-standardized ovarian cancer mortality rates with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S12. Colorectal cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S13. Colorectal cancer incidence trends, females, select countries, 1980-2014 Observed age-standardized colorectal cancer incidence rates among females with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S14. Colorectal cancer mortality trends, females, age-standardized rate (world), select countries, 1975-2014 Observed age-standardized colorectal cancer mortality rates among females with a five-year moving average, select countries, all ages, 1975-2014 Supplementary Figure S15. Lung cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized lung cancer incidence rates among females and age-standardized lung cancer mortality rates among females Supplementary Figure S16. Population using solid fuels for heating and/or cooking, 2013 World map: percent of the population using solid fuels by country Supplementary Figure S17. Adult female smoking prevalence, age 15+ years, 2013 World map: percent of adult females (age 15+ years) who smoke by country, 2013 Supplementary Figure S18. Female youth smoking prevalence, age 13-15 years, 2011 or latest available data World map: percent of female youth (age 13-15 years) who smoke by country, 2011 or latest available data Supplementary Figure S19. Liver cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S20. Hepatitis B virus prevalence, both sexes, from systematic review of studies 1957-2013 World map of HBV prevalence (%) among both sexes combined by country Supplementary Figure S21. Estimated hepatitis C virus prevalence, both sexes, 2005 World map of HCV prevalence (%) among both sexes combined by country Supplementary Figure S22. Liver cancer mortality trends, females, age-standardized rate (world), select countries, 1995-2014 Observed age-standardized liver cancer mortality rates among females with a five-year moving average, select countries, all ages, 1995-2014&lt;/p&gt;

&lt;p&gt;Supplementary Table S1. Leading causes of death among females worldwide, 2012 Number of deaths for top ten causes of death among females worldwide Supplementary Table S2. Leading causes of death among females by world region, 2012 Number of deaths for top ten causes of death among females by world region Supplementary Table S3. Estimated number of new cancer cases and deaths among females by world area, 2012 Number of cancer cases and deaths for all cancer sites combined among females by world region Supplementary Figure S1. Female breast cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized breast cancer incidence rates among females and age-standardized breast cancer mortality rates among females Supplementary Figure S2. Female breast cancer incidence trends, age-standardized rate (world), select countries, 1973-2012 Observed age-standardized female breast cancer incidence rates, select countries, all ages, 1973-2012 Supplementary Figure S3. Female breast cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of breast cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S4. Cervical cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized cervical cancer incidence rates and age-standardized cervical cancer mortality rates Supplementary Figure S5. Prevalence (%) of cervical HPV infection among women by region, all types combined, 1995-2009 World map of HPV prevalence (%) among women by world region Supplementary Table S6. Cervical cancer incidence trends, age-standardized rate (world), select countries, 1975-2007 Observed age-standardized cervical cancer incidence rates with a five-year moving average, select countries, all ages, 1975-2007 Supplementary Figure S7. Cervical cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of cervical cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S8. Uterine corpus cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized uterine corpus cancer incidence rates and age-standardized uterine corpus cancer mortality rates Supplementary Figure S9. Uterine corpus cancer mortality trends, age-standardized rate (world), select countries, 1990-2014 Observed age-standardized uterine corpus cancer mortality rates with a five-year moving average, select countries, all ages, 1990-2014 Supplementary Figure S10. Ovarian cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized ovarian cancer incidence rates and age-standardized ovarian cancer mortality rates Supplementary Figure S11. Ovarian cancer mortality trends, age-standardized rate (world), select countries, 1980-2014 Observed age-standardized ovarian cancer mortality rates with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S12. Colorectal cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S13. Colorectal cancer incidence trends, females, select countries, 1980-2014 Observed age-standardized colorectal cancer incidence rates among females with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S14. Colorectal cancer mortality trends, females, age-standardized rate (world), select countries, 1975-2014 Observed age-standardized colorectal cancer mortality rates among females with a five-year moving average, select countries, all ages, 1975-2014 Supplementary Figure S15. Lung cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized lung cancer incidence rates among females and age-standardized lung cancer mortality rates among females Supplementary Figure S16. Population using solid fuels for heating and/or cooking, 2013 World map: percent of the population using solid fuels by country Supplementary Figure S17. Adult female smoking prevalence, age 15+ years, 2013 World map: percent of adult females (age 15+ years) who smoke by country, 2013 Supplementary Figure S18. Female youth smoking prevalence, age 13-15 years, 2011 or latest available data World map: percent of female youth (age 13-15 years) who smoke by country, 2011 or latest available data Supplementary Figure S19. Liver cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S20. Hepatitis B virus prevalence, both sexes, from systematic review of studies 1957-2013 World map of HBV prevalence (%) among both sexes combined by country Supplementary Figure S21. Estimated hepatitis C virus prevalence, both sexes, 2005 World map of HCV prevalence (%) among both sexes combined by country Supplementary Figure S22. Liver cancer mortality trends, females, age-standardized rate (world), select countries, 1995-2014 Observed age-standardized liver cancer mortality rates among females with a five-year moving average, select countries, all ages, 1995-2014&lt;/p&gt;

&lt;p&gt;Supplementary Table S1. Leading causes of death among females worldwide, 2012 Number of deaths for top ten causes of death among females worldwide Supplementary Table S2. Leading causes of death among females by world region, 2012 Number of deaths for top ten causes of death among females by world region Supplementary Table S3. Estimated number of new cancer cases and deaths among females by world area, 2012 Number of cancer cases and deaths for all cancer sites combined among females by world region Supplementary Figure S1. Female breast cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized breast cancer incidence rates among females and age-standardized breast cancer mortality rates among females Supplementary Figure S2. Female breast cancer incidence trends, age-standardized rate (world), select countries, 1973-2012 Observed age-standardized female breast cancer incidence rates, select countries, all ages, 1973-2012 Supplementary Figure S3. Female breast cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of breast cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S4. Cervical cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized cervical cancer incidence rates and age-standardized cervical cancer mortality rates Supplementary Figure S5. Prevalence (%) of cervical HPV infection among women by region, all types combined, 1995-2009 World map of HPV prevalence (%) among women by world region Supplementary Table S6. Cervical cancer incidence trends, age-standardized rate (world), select countries, 1975-2007 Observed age-standardized cervical cancer incidence rates with a five-year moving average, select countries, all ages, 1975-2007 Supplementary Figure S7. Cervical cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of cervical cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S8. Uterine corpus cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized uterine corpus cancer incidence rates and age-standardized uterine corpus cancer mortality rates Supplementary Figure S9. Uterine corpus cancer mortality trends, age-standardized rate (world), select countries, 1990-2014 Observed age-standardized uterine corpus cancer mortality rates with a five-year moving average, select countries, all ages, 1990-2014 Supplementary Figure S10. Ovarian cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized ovarian cancer incidence rates and age-standardized ovarian cancer mortality rates Supplementary Figure S11. Ovarian cancer mortality trends, age-standardized rate (world), select countries, 1980-2014 Observed age-standardized ovarian cancer mortality rates with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S12. Colorectal cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S13. Colorectal cancer incidence trends, females, select countries, 1980-2014 Observed age-standardized colorectal cancer incidence rates among females with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S14. Colorectal cancer mortality trends, females, age-standardized rate (world), select countries, 1975-2014 Observed age-standardized colorectal cancer mortality rates among females with a five-year moving average, select countries, all ages, 1975-2014 Supplementary Figure S15. Lung cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized lung cancer incidence rates among females and age-standardized lung cancer mortality rates among females Supplementary Figure S16. Population using solid fuels for heating and/or cooking, 2013 World map: percent of the population using solid fuels by country Supplementary Figure S17. Adult female smoking prevalence, age 15+ years, 2013 World map: percent of adult females (age 15+ years) who smoke by country, 2013 Supplementary Figure S18. Female youth smoking prevalence, age 13-15 years, 2011 or latest available data World map: percent of female youth (age 13-15 years) who smoke by country, 2011 or latest available data Supplementary Figure S19. Liver cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S20. Hepatitis B virus prevalence, both sexes, from systematic review of studies 1957-2013 World map of HBV prevalence (%) among both sexes combined by country Supplementary Figure S21. Estimated hepatitis C virus prevalence, both sexes, 2005 World map of HCV prevalence (%) among both sexes combined by country Supplementary Figure S22. Liver cancer mortality trends, females, age-standardized rate (world), select countries, 1995-2014 Observed age-standardized liver cancer mortality rates among females with a five-year moving average, select countries, all ages, 1995-2014&lt;/p&gt;

&lt;p&gt;Supplementary Table S1. Leading causes of death among females worldwide, 2012 Number of deaths for top ten causes of death among females worldwide Supplementary Table S2. Leading causes of death among females by world region, 2012 Number of deaths for top ten causes of death among females by world region Supplementary Table S3. Estimated number of new cancer cases and deaths among females by world area, 2012 Number of cancer cases and deaths for all cancer sites combined among females by world region Supplementary Figure S1. Female breast cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized breast cancer incidence rates among females and age-standardized breast cancer mortality rates among females Supplementary Figure S2. Female breast cancer incidence trends, age-standardized rate (world), select countries, 1973-2012 Observed age-standardized female breast cancer incidence rates, select countries, all ages, 1973-2012 Supplementary Figure S3. Female breast cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of breast cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S4. Cervical cancer incidence and mortality rates, age-standardized rate (world), 2012 Two world maps: age-standardized cervical cancer incidence rates and age-standardized cervical cancer mortality rates Supplementary Figure S5. Prevalence (%) of cervical HPV infection among women by region, all types combined, 1995-2009 World map of HPV prevalence (%) among women by world region Supplementary Table S6. Cervical cancer incidence trends, age-standardized rate (world), select countries, 1975-2007 Observed age-standardized cervical cancer incidence rates with a five-year moving average, select countries, all ages, 1975-2007 Supplementary Figure S7. Cervical cancer survivors diagnosed in last five years (through 2012 or latest available) World map: number of cervical cancer survivors diagnosed within the last five years, per 100,000 population Supplementary Figure S8. Uterine corpus cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized uterine corpus cancer incidence rates and age-standardized uterine corpus cancer mortality rates Supplementary Figure S9. Uterine corpus cancer mortality trends, age-standardized rate (world), select countries, 1990-2014 Observed age-standardized uterine corpus cancer mortality rates with a five-year moving average, select countries, all ages, 1990-2014 Supplementary Figure S10. Ovarian cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized ovarian cancer incidence rates and age-standardized ovarian cancer mortality rates Supplementary Figure S11. Ovarian cancer mortality trends, age-standardized rate (world), select countries, 1980-2014 Observed age-standardized ovarian cancer mortality rates with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S12. Colorectal cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S13. Colorectal cancer incidence trends, females, select countries, 1980-2014 Observed age-standardized colorectal cancer incidence rates among females with a five-year moving average, select countries, all ages, 1980-2014 Supplementary Figure S14. Colorectal cancer mortality trends, females, age-standardized rate (world), select countries, 1975-2014 Observed age-standardized colorectal cancer mortality rates among females with a five-year moving average, select countries, all ages, 1975-2014 Supplementary Figure S15. Lung cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized lung cancer incidence rates among females and age-standardized lung cancer mortality rates among females Supplementary Figure S16. Population using solid fuels for heating and/or cooking, 2013 World map: percent of the population using solid fuels by country Supplementary Figure S17. Adult female smoking prevalence, age 15+ years, 2013 World map: percent of adult females (age 15+ years) who smoke by country, 2013 Supplementary Figure S18. Female youth smoking prevalence, age 13-15 years, 2011 or latest available data World map: percent of female youth (age 13-15 years) who smoke by country, 2011 or latest available data Supplementary Figure S19. Liver cancer incidence and mortality rates, females, age-standardized rate (world), 2012 Two world maps: age-standardized liver cancer incidence rates among females and age-standardized liver cancer mortality rates among females Supplementary Figure S20. Hepatitis B virus prevalence, both sexes, from systematic review of studies 1957-2013 World map of HBV prevalence (%) among both sexes combined by country Supplementary Figure S21. Estimated hepatitis C virus prevalence, both sexes, 2005 World map of HCV prevalence (%) among both sexes combined by country Supplementary Figure S22. Liver cancer mortality trends, females, age-standardized rate (world), select countries, 1995-2014 Observed age-standardized liver cancer mortality rates among females with a five-year moving average, select countries, all ages, 1995-2014&lt;/p&gt;